To the Editor: Liraglutide and cardiovascular outcomes in type 2 diabetes

New England Journal of Medicine

Volumn 375, Issue 18, 2016, Pages 1797-1798

  Alvarez Villalobos, Neri A ^a   Trevino Alvarez, Andres M ^a   Gonzalez Gonzalez, Jose G ^b  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

CANCER INCIDENCE; CARDIOVASCULAR RISK; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; TREATMENT OUTCOME;

CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; TREATMENT OUTCOME;

EID: 84994087424     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1611289     Document Type: Letter

References (3)

1. Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013; 36: Suppl 2: S245-52
2. Chalmer T, Almdal TP, Vilsboll T, Knop FK. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes - focus on pancreatitis and pancreas cancer. Expert Opin Drug Saf 2015; 14: 171-80
3. Renner S, Blutke A, Streckel E, Wanke R, Wolf E. Incretin actions and consequences of incretin-based therapies: Lessons from complementary animal models. J Pathol 2016; 238: 345-58.